<- Go Home
Vyant Bio, Inc.
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson’s disease (PD). The company is based in Cherry Hill, New Jersey.
Market Cap
$1.2M
Volume
153.2K
Cash and Equivalents
$2.8M
EBITDA
-$13.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$339.0K
Profit Margin
85.39%
52 Week High
$1.58
52 Week Low
$0.14
Dividend
N/A
Price / Book Value
0.27
Price / Earnings
-0.09
Price / Tangible Book Value
0.27
Enterprise Value
-$861.2K
Enterprise Value / EBITDA
0.07
Operating Income
-$13.7M
Return on Equity
122.41%
Return on Assets
-51.76
Cash and Short Term Investments
$2.8M
Debt
$708.0K
Equity
$4.5M
Revenue
$397.0K
Unlevered FCF
-$9.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium